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Abstract  
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is reported to 
induce EGFR internalization in colorectal cancer (CRC) cells. However, the biological 
relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the 
relevance of EGFR downregulation with anti-EGFR mAb to anti-tumor activity in CRC cells 
was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was 
assessed by flow cytometry, and its growth-inhibitory effects were measured by trypan 
blue-exclusion, in 10 RAS, BRAF wild-type CRC cell lines, but there was no significant 
correlation between EGFR number and its growth-inhibitory effect. However, a significant 
correlation existed between the percentage decrease in the number of EGFRs after cetuximab 
treatment and its growth-inhibitory effect in those cell lines. Treatment with TGF-α, a ligand 
for EGFR, induced EGFR internalization in CRC cells, but most EGFRs subsequently 
recycled to the cell surface, consistent with previous studies. While cetuximab treatment 
induced EGFR internalization, most receptors subsequently translocated into the late 
endosome, leading to lysosomal degradation, as revealed by immunoblotting and double 
immunofluorescence. Cetuximab-sensitive CRC cells showed greater EGFR internalization, 
stronger cell growth inhibition, and more augmented apoptotic signals than non-sensitive cells. 
Immunohistochemistry (IHC) for EGFR, performed using an EGFR pharmDx™kit (mouse 
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anti-human EGFR mAb clone 2-18C9), in clinical specimens before and after anti-EGFR 
mAb therapy in 13 CRC patients showed a significant correlation between the response to 
anti-EGFR mAb and decreased staining after therapy. 
 
Implications: This report clearly demonstrates that anti-EGFR mAb facilitates internalization 
and subsequent degradation of EGFRs in lysosomes, which is an important determinant of the 
efficacy of anti-EGFR mAb treatment for CRC. 
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Introduction 
Epidermal growth factor receptor (EGFR) represents a unique target in cancer 
therapy because overexpression of EGFRs has been implicated in the pathogenesis of many 
malignant tumors, such as head and neck cancer, colorectal cancer (CRC), lung cancer, 
ovarian cancer, cervical cancer, and gastric cancer (1-6). There are two therapeutic strategies 
targeting EGFRs: monoclonal antibodies (mAbs) and tyrosine kinase inhibitors against EGFR. 
While kinase inhibitors bind to the intracellular domain of the EGFR and block kinase activity, 
antibodies target the extracellular part of the receptor, thereby preventing ligand binding, 
conformational activation, and/or receptor dimerization (7-9). For patients with metastatic 
CRC (mCRC), two mAbs targeting EGFR, cetuximab and panitumumab, have been proven to 
be effective in combination with chemotherapy or as monotherapy (10-15). However, recently 
it has been shown that these drugs are ineffective in CRCs with RAS mutation, which causes 
constant oncogenic activation of RAS/MEK/ERK signal transduction at the EGFR 
downstream. Thus, RAS mutation is the only established biomarker for selection of patients 
with mCRC. Moreover, numerous studies have investigated the association of EGFR 
molecular events with the response to EGFR mAbs and have demonstrated that the levels of 
expression or somatic mutations of EGFR did not correlate with clinical responses to 
cetuximab and panitumumab. Thus, the response to EGFR mAbs varies among individuals 
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and cannot be universally expected even in the RAS wild-type mCRC, which presents a 
significant problem in clinical practice.  
Anti-EGFR mAbs bind to domain III of the EGFR and inhibit binding of activating 
ligands (16). They also have a cytotoxic effect by inducing antibody-dependent cellular 
cytotoxicity (ADCC) and can counteract tumor growth through several different mechanisms 
(17). One important mechanism to counteract cancer cell proliferation is induction of receptor 
internalization and downregulation. The mouse anti-EGFR mAb (clone 225) has been shown 
to induce endocytosis of the EGFR (18,19). However, antibody-dependent EGFR dynamics 
are very complex, and the mechanism and pattern of cetuximab-induced downregulation of 
EGFR in CRC is not fully understood. Moreover, it is unclear whether antibody-induced 
EGFR internalization is related to the antibody’s biological activity. Therefore, we have in the 
current study investigated how antibody-induced EGFR downregulation is associated with 
anti-tumor activity in CRC cells. Our results suggest that the degree of EGFR degradation is a 
more important determinant of cetuximab treatment efficacy than the initial number of 
EGFRs on the cell surface. Furthermore, we demonstrated that cetuximab binding to EGFR 
augments EGFR downregulation due to its translocalization to the late endosome, leading to 
lysosomal degradation. These studies provide new clinical insight into the mechanism of 
responsiveness to anti-EGFR antibody therapy. 
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Materials and Methods 
Cell culture and reagents 
We used 22 CRC cell lines. Of these, CoCM-1, COLO201, COLO320DM, CCK-81, 
DLD-1, and OUMS-23 cell lines were purchased from the Health Science Research Resources 
Bank (HSRRB, Tokyo, Japan). Caco-2, HCT116, HT29, LS174T, SW48, SW480, SW1417, 
and T84 cell lines were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA). HCA-7, HCA-46, LIM1215, and HT55 cell lines were obtained from the 
European Collection of Authenticated Cell Cultures (ECACC, Salisbury, Wilshire, UK). 
COLO205, JHCOLOYI and PMF-ko14 were obtained from RIKEN BioResource Center 
(RIKEN BRC, Ibaraki, Japan). The M7609 cell line was kindly provided by Dr. R. Machida 
(Hirosaki University, Hirosaki, Japan). All cell lines were originally received from 2009 to 
2014 and authenticated by short tandem repeat assay at BEX Co., Ltd (Tokyo, Japan) in 2016. 
No specific authentication of the M7609 cell line was performed. All cell lines were cultured 
in recommended media supplemented with fetal bovine serum (FBS) at 37 °C with CO2, as 
described in Supplementary Table S1. Cetuximab was purchased from Merck Co., Ltd. 
(Darmstadt, Germany). A recombinant human epidermal growth factor (EGF) was obtained 
from Pepro Tech Inc. (Rocky Hill, NJ). Recombinant human transforming growth factor-α 
(TGF-α) and amphiregulin were obtained from Wako Co., Ltd. (Tokyo, Japan). 
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2-Mercaptoethanesulfonic acid sodium (MesNa) and iodoacetamide were obtained from 
Sigma-Aldrich (St Louis, MO). 
 
Mutational analyses of KRAS, NRAS, BRAF, PIK3CA, and EGFR 
Genomic DNA was extracted from each cell line using a QIAamp Mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. KRAS (codon 12, 13) and 
BRAF (codon 600) and EGFR ectodomain (exon 12) mutations were detected by direct 
sequencing using an ABI PRISM
®
 3100 Genetic Analyzer (Applied Biosystems, Hitachi, 
Japan). Mutations in KRAS (codons 61, 146), NRAS (codons 12, 13, 61), and PIK3CA (codon 
1047) were detected by Luminex assay. We excluded PIK3CA codon 542, 545, and 546 
mutational analysis because it has already been shown that they have no significant effect on 
the response to cetuximab treatment (20). Mutations in the intracellular domain of EGFR 
were detected by the peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp 
method (21,22). This technique detects several EGFR mutations including G719S, G719C, 
G719A, T790M, L858R, L861Q, and exon 19 deletions. 
 
Cell viability assay 
10 
 
 Cell viability was determined using the trypan blue dye exclusion method. Each cell 
line (1.0 × 10
5 
cells) was plated in a 6-well plate and incubated in medium with 10% FBS in 
the presence of cetuximab (30 nM) or vehicle only. Viable cells were counted at day 4 and day 
7 using a Countess II automated cell counter (Thermo Fisher Scientific, Inc., Waltham, MA). 
The growth inhibition rate was calculated as the ratio of the cell number in the presence of 
cetuximab to that in the presence of vehicle only. 
 
Quantification of cell surface EGFR by flow cytometry 
Cells were washed and then detached using trypsin and EDTA at 37 °C. Trypsin was 
inactivated by adding a soybean trypsin inhibitor (Wako). The cells were then incubated with 
mouse anti-human EGFR monoclonal antibody (sc-120, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) on ice for 45 minutes. After washing the cells 3 times with 10 mM phosphate 
buffered saline (PBS) supplemented with 0.1% bovine serum albumin (BSA), they were 
further incubated with 100 µl of FITC-conjugated F(ab’)2 fragment of goat anti-mouse IgG 
polyclonal antibody (Dako, Glostrup, Denmark) in the dark on ice for 45 minutes. The 
staining of cells with mAb were analyzed using a Beckman Coulter EPICS XL-MCL Flow 
Cytometer (Beckman Coulter, Krefeld, Germany). Quantification of EGFR on the cell surface 
was performed using Dako QIFKIT
®
 (Dako) according to the manufacturer’s instructions. 
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Briefly, 5 populations of calibration beads, bearing different numbers of mAb molecules, were 
analyzed by flow cytometry. The mean fluorescence intensity of each population of beads was 
used for construction of a calibration curve for antibody-binding capacity (ABC). The ABC of 
the cells analyzed by flow cytometry was calculated by interpolation from the calibration 
curve.  
 
Western blot analysis 
Cells were rinsed in cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 
150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium 
dodecyl sulfate [SDS]). Total protein concentration in the lysates was determined using a 
BCA protein assay kit (Thermo Fisher Scientific Inc., Waltham, MA). Protein lysates were 
subjected to SDS-polyamide gel electrophoresis (SDS-PAGE) and then transferred to a 
polyvinylidene difluoride (PVDF) membrane. After blocking using 5% fat-free dry milk in 
Tris-buffered saline with 0.1% Tween (TBS-T) for 1 hour at room temperature, the 
membranes were probed with rabbit anti-human EGFR polyclonal antibody (sc-03, Santa 
Cruz Biotechnology, Inc.), rabbit anti-human ERK polyclonal antibody (sc-94, Santa Cruz 
Biotechnology, Inc.), rabbit anti-human phosphorylated ERK (p-ERK) monoclonal antibody 
(#4377, Cell Signaling Technology, Tokyo, Japan), or rabbit anti-human PARP polyclonal 
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antibody (#9542, Cell Signaling Technology) at 4 °C overnight. The membranes were then 
washed with TBS-T and incubated with the corresponding secondary horseradish-conjugated 
goat anti-rabbit antibodies (GE Healthcare UK, Ltd., Buckinghamshire, UK) at room 
temperature for 1 hour. After washing in TBS-T, the immunoblots were visualized using ECL 
detection reagents (GE Healthcare UK, Ltd). β-actin (Sigma-Aldrich) was used as a loading 
control. 
 
Biotinylation Assay 
Cells were serum-starved for 24 hours prior to the assay, washed with ice-cold PBS 
twice, and incubated with 0.5 mg/ml biotin (EZ-link Sulfo-NHS-SS-Biotin, Thermo 
Scientific) for 30 minutes at 4 °C. Subsequently, biotin was quenched with 50 mM NH4Cl. 
Cells were then scraped gently, rinsed with TBS, and lysed with lysis buffer (50 mM Tris-HCl, 
pH 8.0, 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS). 
Equal amount of protein was added to 500 µL of 50% streptavidin-agarose beads 
(NeutrAvidin Agarose Resin, Thermo Scientific) and incubated for 60 minutes at room 
temperature. The beads were then rinsed with wash buffer 3 times and incubated with 50 mM 
DTT to cleave disulfide bonds in avidin-biotin-labeled protein. Protein was eluted with 
SDS-PAGE sample buffer and subjected to Western blot analyses. 
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Biotinylation-based EGFR internalization assay 
 CCK-81 and Caco-2 cells were serum-starved for 24 hours prior to the assay and 
washed in ice-cold PBS twice. Surface proteins were then biotinylated with 0.5 mg/ml 
sulfo-NHS-SS-biotin for 30 minutes at 4 °C, followed by washing with TBS and placement 
on ice. For internalization, cells were incubated in pre-warmed MEM containing 30 nM 
cetuximab at 37 °C for 10 minutes, whereas the control cells were incubated with vehicle 
alone. Surface biotin was then stripped from the cells with a 10 minutes incubation in 50 mM 
MesNa in TBS, followed by washing and quenching MesNa with 20 mM iodoacetamide in 
TBS for 10 minutes. The cells were subsequently lysed, precipitated with 50% 
streptavidin-agarose beads, and subjected to Western blot analyses.  
 
Double immunofluorescence 
Cells were fixed with 4% paraformaldehyde for 30 minutes and permeabilized with 
0.25% Triton X-100 in PBS for 5 minutes. After blocking using 5% BSA in PBS with 0.03% 
Triton X-100 for 1 hour at room temperature, the cells were incubated with anti-EGFR Alexa 
Fluor
®
 488-conjugated rabbit monoclonal antibody (#5616, Cell Signaling Technology) and 
anti-LAMP-1 Alexa Fluor
®
 647-conjugated mouse monoclonal antibody (H4A3, BioLegend, 
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Inc., San Diego, CA) for 2 hours at room temperature. Cells were then washed thoroughly 
with PBS and mounted with Prolong
®
 Gold antifade reagent with DAPI (Thermo Fisher 
Scientific Inc.). Fluorescent images were obtained using a Nikon A1 confocal microscope 
(Nikon Corporation, Tokyo, Japan). 
 
Patients 
Thirteen patients with CRC whose tissues were available before and after anti-EGFR 
mAb treatment by surgical resection or endoscopic biopsies were enrolled. Baseline 
characteristics of the patients are shown in Table 1. The cohort consisted of 10 men and 3 
women, with a median age of 59 years (range 36 – 72 years). Of the 13 patients, 9 were 
treated with cetuximab-containing therapy and 4 with panitumumab-containing therapy. Four 
patients had received prior treatment. The median time from the last dose of anti-EGFR mAbs 
to acquisition of tissue was 27 days. The response to anti-EGFR therapy was evaluated by 
computed tomography (CT) according to the Response Evaluation Criteria in Solid Tumors 
(RECIST; version 1.1). Patients were classified as either responders (confirmed complete 
response [CR], or partial response [PR]) or non-responders (stable disease [SD] or 
progressive disease [PD]) based on the best response evaluated by RECIST. The present study 
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was approved by the Institutional Review Board of Tokushima University Hospital and 
informed consent was obtained from all patients. 
 
Immunohistochemistry (IHC) 
Immunohistochemical staining for EGFR in CRC tissue was performed using an 
EGFR pharmDx™ kit (Dako) according to the manufacturer’s instructions. Briefly, 4-μm 
paraffin-embedded tissue sections were deparaffinized, incubated with proteinase K solution, 
and treated with 3% H2O2 to block endogenous peroxidase. They were then incubated with a 
mouse anti-human EGFR mAb (clone 2-18C9) at 4 °C overnight. They were washed with 
PBS and incubated with horseradish peroxidase (HRP)-conjugated polymers at room 
temperature for 30 minutes, followed by visualization with DAB (3, 3’-diaminobenzidine 
tetrahydrochloride). Finally, the slides were counterstained with hematoxylin. 
Positive staining was evaluated and classified based on IHC scores (0, 1, 2 or 3) 
according to the percentage of positive cells and staining intensity, as described by Chung and 
colleagues with a minor modification (23). The IHC score designations were as follows: 0, no 
membranous staining in any tumor cells; 1, staining of less than 10% of tumor cells with any 
intensity or in less than 30% of tumor cells with weak intensity; 2, staining in 10% to 30% of 
tumor cells with moderate to strong intensity or staining in 30% to 50% of tumor cells with 
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weak to moderate intensity; and 3, staining in more than 30% of tumor cells with strong 
intensity or more than 50% of tumor cells with any intensity. Immunoreactivity was evaluated 
independently by 2 investigators (Y.O. and T.T). Cases with discrepancies were jointly 
reevaluated and a consensus was reached. Changes in IHC scores before and after treatment 
were then categorized into 3 groups; “no change” showing the same IHC scores before and 
after treatment, “moderate decrease” showing a 1 scale reduction after treatment, and “marked 
decrease” showing more than a 2 scale reduction after treatment. 
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Results 
Growth-inhibitory effect of cetuximab differs in the various RAS, RAF wild-type CRC 
cell lines 
Among the 22 CRC cell lines examined, 10 cell lines (CoCM-1, COLO320DM, 
CCK-81, Caco-2, HCA-7, HCA-46, LIM1215, HT55, PMF-ko14, and JHCOLOYI) were 
both KRAS (codon 12, 13) wild-type and BRAF wild-type (Supplementary Table S2). 
Moreover, we analyzed the mutation status of KRAS (codons 61 and 146), NRAS (codons 12, 
13 and 61), PIK3CA (codon 1047), and EGFR (exon 12 and exon 18-21) in these 10 cell lines 
and confirmed that there were no mutations in these genes. We then evaluated the inhibitory 
effect of cetuximab on cell growth in these 10 RAS, RAF wild-type CRC cell lines (Figure 1). 
The growth of CCK-81, LIM-1215, and HCA-7 cell lines was inhibited by more than 80% at 
7 days after cetuximab treatment. Conversely, the growth of COLO320DM and PMF-ko14 
was negligibly inhibited by cetuximab treatment. The remaining cell lines showed 
approximately 30% to 70% inhibition of cell growth at 7 days after cetuximab treatment. Thus, 
the growth-inhibitory effect of cetuximab varied even among RAS, RAF wild-type cell lines. 
These results are consistent with clinical findings that the response to cetuximab differs even 
among cancers with no mutation in the EGFR signaling pathway.  
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Decrease in cell surface EGFRs correlates with the anti-tumor activity of cetuximab  
To assess the relationship between the number of EGFRs and the efficacy of 
cetuximab, we measured the number of EGFRs on the cell surface by flow cytometry in the 
10 cell lines before and after addition of cetuximab (Figure 2A). The initial number of EGFRs 
on the cell surface varied among the cell lines. HCA-7, PMF-ko14, and LIM-1215 cells had 
more than 20,000 EGFRs per cell, whereas JHCOLOYI and COLO320DM cells had less than 
1,000 per cell. After addition of cetuximab, the number of EGFRs on the cell surface 
decreased in all cell lines due to cetuximab-induced internalization of EGFR. However, the 
degree of EGFR internalization varied among the cell lines. When we compared the initial 
number of EGFRs on the cell surface with the growth-inhibitory effect of cetuximab, no 
significant relationship was observed (p=0.141) (Figure 2B). However, the percentage 
decrease in the number of EGFRs correlated significantly with the degree of growth inhibition 
by cetuximab (p=0.040) (Figure 2C), suggesting that the degree of EGFR internalization 
correlates with the response to anti-EGFR treatment. 
 
Cetuximab induces EGFR internalization and lysosomal degradation 
To clarify the mechanism by which cell surface EGFRs decreased in 
cetuximab-sensitive CRC cells, we first compared the binding affinity of cetuximab to cell 
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surface EGFR between cetuximab-sensitive and non-sensitive cell lines. However, we found 
no significant difference in the affinity of cetuximab for EGFR on the cell surface between 
cetuximab-sensitive cells and non-sensitive cells (Supplementary Figure S1). It has been 
reported that EGFR ligands such as EGF and TGF-α stimulate receptor internalization, 
leading to intracellular degradation or recycling of EGFR to the cell surface (24-26). 
Cetuximab, an anti-EGFR mAb, also has been reported to induce EGFR internalization, 
similarly to the activating ligands (18). To compare differences in EGFR trafficking after 
internalization, CCK-81 cells, which showed appreciable EGFR internalization with treatment, 
were incubated with the activating ligand TGF-α or cetuximab, and the chronological changes 
in EGFR numbers on the cell surface were examined. After stimulation with TGF-α, the 
EGFR number on the cell surface decreased by approximately 50% in 15 minutes, then close 
to 100% of the receptor recycled back to the cell surface, consistent with a previous report 
(25). After stimulation with cetuximab, however, about 80% of EGFRs were internalized, and 
very little EGFR was recycled back to the cell surface (Figure 3A). Interestingly, when we 
observed cells up to 24 hours after cetuximab treatment, a majority of the internalized EGFRs 
were not recycled back to the cell surface over time (Supplementary Figure S2). To extend 
these observations using a biotinylation approach, the cell surface proteins in CCK-81 cells 
treated with TGF-α or cetuximab were labeled with biotin, precipitated, and subjected to 
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Western blot analysis using anti-EGFR antibody. As shown in Figure 3B, levels of EGFR on 
the cell surface decreased 30 minutes after the addition of both activating ligand and 
cetuximab, indicating EGFR internalization to the cytoplasm. However, whereas cells treated 
with TGF-α returned most of the internalized EGFRs back to the surface, cells treated with 
cetuximab recycled significantly less EGFR, suggesting that the ligand and antibody have 
very different effects on EGFR trafficking. Moreover, although the total amount of EGFR in 
whole cell lysates did not change after stimulation with TGF-α, the total amount of EGFR 
decreased markedly over time after stimulation with cetuximab, demonstrating that the 
majority of cetuximab-internalized EGFR was degraded in the cells.  
To confirm the degradation of EGFR in cells treated with cetuximab, the 
colocalization of EGFR with LAMP-1, which is located in lysosomes and helps to regulate 
endocytic trafficking and degradation, was examined by double immunofluorescence. 
Representative staining patterns are shown in Figure 3C. Before treatment with cetuximab or 
TGF-α, EGFR was predominantly distributed on the cell membrane of the CRC cells. After 
treatment with TGF-α, EGFR immunostained signal was translocated into the cytoplasm and 
a majority of the immunostained EGFR had not merged with LAMP-1-positive vesicles. After 
treatment with cetuximab, however, EGFR signal was also translocated into the cytoplasm 
and showed overlap with LAMP-1-positive signals. Figure 3D shows image quantification of 
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the merged signals of EGFR and LAMP-1. CCK-81 cells treated with cetuximab showed 
significantly more merged signals than cells treated with activated ligand (TGF-α). These 
results indicate that internalized cetuximab-EGFR complex is directed to lysosomes for 
degradation. Thus, it appears that, although both ligand and cetuximab induce receptor 
internalization, the fates of the internalized ligand-EGFR and cetuximab-EGFR complexes 
are different: the ligand-EGFR complex is directed to receptor recycling, but 
cetuximab-EGFR complex is directed to endosomal degradation. 
 
Cetuximab-dependent EGFR internalization correlates with decreased MAP kinase 
signaling 
We first observed the amount of internalized EGFR in CCK-81 
(cetuximab-responsive) and Caco-2 (non-responsive) cell lines using a biotinylation-based 
EGFR internalization assay. As shown in Figure 4A, we confirmed EGFR internalization after 
treatment with cetuximab occurred more efficiently in CCK-81 cells than in Caco-2 cells. To 
determine whether a decrease in the number of EGFRs on the cell surface is associated with 
signal transduction downstream of EGFR, we investigated p-ERK and ERK expression in 
CCK-81 and Caco-2 cells by Western blotting after treatment with cetuximab (Figure 4B). In 
CCK-81 cells, which showed marked EGFR internalization, phosphorylation of ERK was 
22 
 
strongly inhibited by addition of cetuximab. On the other hand, Caco-2, in which EGFR was 
less internalized after addition of cetuximab, showed a moderate inhibitory effect of 
cetuximab on ERK phosphorylation. Densitometric analysis confirmed that cetuximab had a 
stronger inhibitory effect on the MAP kinase signaling pathway in CCK-81 than in Caco-2 
cells (Figure 4C). To further investigate the induction of apoptosis in these cells, we evaluated 
the cleavage of poly (ADP-ribose) polymerase (PARP) by Western blotting (Figure 4D). The 
cleavage of PARP was markedly increased by addition of cetuximab in CCK-81 cells, but it 
was only faintly apparent in Caco-2 cells, indicating that apoptosis was induced to a greater 
extent in CCK-81 cells than in Caco-2 cells. 
 
EGFR degradation in CRC tissue is associated with the tumor response to anti-EGFR 
treatment 
To assess the clinical relevance of the in vitro findings, we investigated changes in 
EGFR expression after anti-EGFR mAb treatment in cancer tissues from 13 CRC patients in 
association with response to the treatment. Figure 5A shows representative staining patterns 
of EGFR before and after treatment: i.e., marked decrease (Case 5, Figure 5A, a-c), moderate 
decrease (Case 12, Figure 5A, d-f), and no change (Case 9, Figure 5A, g-i). Cancerous tissue 
from Case 5 showed strong EGFR staining (IHC score 3+) before treatment (Figure 5A, b), 
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but few signals for EGFR were seen after treatment (IHC score 0, Figure 5A, c). This case 
was categorized as a marked decrease. Similarly, in Case 12 EGFR was strongly stained in the 
majority of cancer cells before treatment (IHC score 3+), but 50% of the cells showed 
moderate to weak staining signals (IHC score 2+) after treatment. Thus, this case was 
classified as a moderate decrease. The IHC scores before and after the treatment in Case 9 
were equal (IHC score 3+), so this case was categorized as no change. Out of a total of 13 
cases, there was 1 case with marked decrease, 5 cases with moderate decrease, and 7 cases 
with no change. When we compared responders and non-responders to anti-EGFR mAb 
treatment, the former showed a significantly greater change in EGFR expression after 
treatment than did non-responders (p<0.01) (Figure 5B, C). This result supports the in vitro 
finding that the percentage decrease in the number of EGFRs on the cell surface correlates 
with the anti-tumor activity of anti-EGFR mAb and reveals a close relationship between 
EGFR degradation and clinical effectiveness of anti-EGFR mAb agents. 
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DISCUSSION 
In this study, we have shown that the degree of EGFR internalization varies in RAS 
wild-type CRC cells and is closely associated with the sensitivity to anti-EGFR antibodies. 
We also demonstrated that downregulation of EGFR on the cell surface after anti-EGFR 
antibody treatment is caused by augmented degradation of antibody-bound receptor via the 
endosomal-lysosomal pathway, resulting in inhibition of cell growth signals and activation of 
apoptotic signals. Moreover, our theory was supported by analyzing clinical samples of CRC 
from patients who received anti-EGFR therapy.   
We did not find a significant correlation between the initial number of EGFRs on the 
cell surface and anti-tumor activity of cetuximab in RAS wild-type CRC cell lines. This result 
is consistent with recent clinical findings that the initial EGFR expression level is not 
significantly correlated with the clinical response to cetuximab and panitumumab, as revealed 
by IHC (11,23,27) and quantitative real-time polymerase chain reaction (28). Similarly, the 
result is consistent with recent studies showing no significant correlation between EGFR gene 
copy number and response to cetuximab, as determined by fluorescent in situ hybridization 
(FISH) (29,30). Interestingly, however, we found that downregulation of EGFR by anti-EGFR 
antibody significantly correlated with the rate of inhibition of cell proliferation. Moreover, 
inhibition of growth-promoting signals and activation of apoptotic signals were observed 
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depending on the degree of downregulation of EGFR on the surface of CRC cells. In addition, 
we found a significant correlation between attenuation of EGFR expression and therapeutic 
efficacy in cancer tissue from patients who received anti-EGFR antibody therapy. Thus, we 
were able to demonstrate a close correlation between EGFR downregulation in cancer tissue 
and efficacy of anti-EGFR antibody therapy in patients with CRC, as well as in CRC cell lines 
in vitro.       
Several previous studies have investigated the mechanism of internalization and 
subsequent trafficking of EGFR induced by its ligands, including TGF-α and EGF (31). 
However, a few studies have produced contradictory results in terms of anti-EGFR 
antibody-induced receptor trafficking. Sunada and associates reported that 225 mAb 
(cetuximab) stimulated EGFR internalization and induced its downregulation to an extent 
comparable to that induced by ligands using the human epidermoid carcinoma cell line A431 
(18). Jaramillo and coworkers reported that antibody-bound EGFR is less internalized and 
more recycled to the cell surface than ligand-bound EGFR in the human lung carcinoma cell 
lines A549, CL1-0, and CL1-5 (32). In the present study, however, we found augmented 
degradation of EGFR after cetuximab stimulation in the CRC cell line CCK-81. This is also 
supported by the fact that phosphorylation of EGFR was augmented by stimulation with 
ligands (TGF-α > amphiregulin) but was not augmented by treatment with cetuximab, with 
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respect to both cell surface protein and total protein (Supplementary Figure S3). Therefore, 
we next examined the localization of EGFR after antibody-induced internalization by double 
immunofluorescence and found that the majority of antibody-bound EGFR was indeed 
translocated to the late endosome after cetuximab treatment, leading to subsequent lysosomal 
degradation. Similar results were obtained using the CRC cell line LIM-1215 (data not 
shown). Moreover, results consistent with these in vitro findings were obtained by analyzing 
clinical CRC tissues before and after anti-EGFR mAb treatment. Our data demonstrate that 
anti-EGFR antibody efficiently induces degradation of EGFR via the endosomal/lysosomal 
pathway. Recently, Berger and colleagues reported a different mechanism for EGFR 
internalization between antibody and ligand stimulation: i.e., ligand-induced internalization 
was clathrin-dependent but antibody-induced internalization was clathrin-independent (33). 
This report also supports our theory that the localization and trafficking of antibody-bound 
EGFR are different from those of ligand-bound EGFR; ligand-bound EGFR is destined 
predominantly for recycling but antibody-bound EGFR, predominantly for lysosomal 
degradation. These findings are quite consistent with the data showing that EGFR 
downregulation is significantly correlated with the efficacy of anti-EGFR antibody treatment. 
Thus, our data suggest that EGFR trafficking and degradation after antibody-binding is a key 
mechanism of responsiveness to anti-EGFR antibody therapy.     
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Recently, early tumor shrinkage (ETS) and depth of response have received much 
attention as predictors of treatment outcomes for long-term survival (34,35). In particular, 
ETS has been achieved more frequently with treatment protocols that include anti-EGFR 
antibodies for RAS wild-type. The present study revealed that EGFR was rapidly 
downregulated in cetuximab-sensitive CRC cell lines after exposure to cetuximab, leading to 
strong inhibition of cell growth and enhanced apoptosis. This rapid EGFR downregulation is 
explained by efficient EGFR degradation in lysosomes without recycling to the cell surface. 
When the 13 patients with mCRC enrolled in this study were divided into ETS and non-ETS 
groups, there was a significant difference in EGFR downregulation by IHC (Supplementary 
Table S3). In this context, our results may explain the clinical phenomenon of ETS following 
treatment with anti-EGFR antibodies: i.e., ETS is achieved by rapid EGFR downregulation 
and subsequent growth inhibition and augmentation of apoptosis. ADCC is proposed as one of 
the mechanisms of cetuximab anti-tumor activity. ADCC activity is reportedly correlated with 
the absolute number of EGFRs on the cell surface, irrespective of the presence of RAS 
mutation and RAF mutation (36). Therefore, the correlation between the percentage decrease 
in the EGFR number, ADCC activity, and therapeutic effect is unclear in this study. In vivo 
experiments will be needed for a more detailed analysis.          
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Currently, the exact molecular mechanisms for antibody-induced EGFR 
downregulation have not been fully clarified. Although further investigations are needed to 
identify which molecules are involved in this marked degradation of EGFR, this is the first 
report addressing the clinical significance of EGFR degradation in anti-EGFR antibody 
therapy. These findings provide new insights to better understand the mechanism of action of 
anti-EGFR antibodies and will help to identify new positive predictors of EGFR signaling 
blockade. 
In conclusion, downregulation of EGFRs after treatment with anti-EGFR antibody 
was significantly correlated with the treatment’s anti-tumor activity in RAS wild-type CRC 
cell lines. Antibody-bound EGFR was efficiently degraded via the endosomal/lysosomal 
system, leading to inhibition of cell proliferation and augmentation of apoptosis. The 
correlation between EGFR downregulation and response to anti-EGFR antibodies was 
confirmed in patients with CRCs receiving treatment with anti-EGFR antibodies.    
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Figure legends 
Figure 1. 
Growth inhibitory curves of various RAS, RAF wild-type colorectal cancer (CRC) cell lines 
with cetuximab treatment. Each cell line was incubated with cetuximab (30 nM) or vehicle 
only. After 4 days and 7 days, the cells were detached and the cell number was counted using 
the trypan blue method. The cell-growth inhibition rate was calculated as the ratio of the 
number of cells treated with cetuximab to the number of cells treated with vehicle only. All 
experiments were performed independently at least 3 times. 
 
Figure 2.   
EGFR internalization induced by addition of cetuximab and its growth inhibitory effect on 
CRC cell lines. A) EGFR number on the cell surface before and after addition of cetuximab. 
After starvation for 24 hours, the cells were incubated with cetuximab (30 nM) for 7 days. 
Subsequently, the EGFR number was determined by flow cytometry. Values are mean ± 
standard deviation (SD) from 3 independent experiments. B) Correlation between cell growth 
inhibition rate and initial EGFR number on the cell surface (per cell). C) The correlation 
between the rate of cell growth inhibition and percentage decrease in EGFR number was 
calculated from the absolute decrease in EGFR number after addition of cetuximab divided by 
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the initial EGFR number. P-values were determined using Pearson’s correlation coefficient 
test. R
2
 indicates the coefficient of determination. 
 
Figure 3.  
EGFR ligand and cetuximab differentially affect EGFR trafficking. A) Chronological changes 
in the number of EGFRs on the cell surface. CCK-81 cells were incubated with TGF-α (20 
nM) or cetuximab (30 nM) for 60 minutes on ice, washed, and incubated at 37 °C for different 
time periods. At the specified time points, surface receptors were quantified by flow 
cytometry. All experiments were performed independently at least 3 times. P-values were 
determined using Student’s t test. *p <0.01. B) CCK-81 cells were incubated with TGF-α (20 
nM) or cetuximab (30 nM) for 60 minutes on ice, washed, and incubated at 37 °C for different 
time periods. The cells were then incubated on ice with streptavidin-conjugated biotin to label 
cell surface proteins. Biotinylated cell surface proteins were precipitated using 
streptavidin-agarose beads and subjected to Western blot analysis for EGFR. Whole cell 
lysates for each set were also extracted and subjected to Western blot analyses. C) EGFR 
co-localization with LAMP-1 in CCK-81 cells. CCK-81 cells were incubated with TGF-α (20 
nM) or cetuximab (30 nM) for 30 minutes and fixed in 4% paraformaldehyde. The cells were 
then labeled for EGFR (green) and LAMP-1 (red) as described in Materials and Methods. Bar, 
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10 µm. D) Quantification of the merged signal of EGFR colocalizing with LAMP-1 in cells 
treated with cetuximab (30 nM) or TGF-α (20 nM). Y-axis of the graph shows merged levels 
from an average of 5 cells for each condition. P-value was determined using Student’s t test. 
*p <0.01. 
 
Figure 4.  
Effect of cetuximab on cell growth and apoptotic signals. A) Surface proteins on CCK-81 and 
Caco-2 cells were biotinylated with 0.5 mg/ml streptavidin-conjugated sulfo-NHS-SS-biotin 
for 30 minutes at 4 °C. The cells were incubated in prewarmed MEM containing 30 nM 
cetuximab at 37 °C for 10 minutes. Surface biotin was stripped from the cells with a 
10-minutes incubation in 50 mM MesNa. The cells were subsequently lysed, precipitated with 
50% streptavidin-agarose beads, and subjected to Western blot analyses for EGFR. Whole cell 
lysates of each set were also extracted and subjected to Western blot analyses to confirm that 
there was difference in the total amount of EGFR between control and cetuximab-treatment 
groups. B) Expression of p-ERK and ERK in CCK-81 or Caco-2 cells. CCK-81 cells 
(sensitive to cetuximab) or Caco-2 cells (less sensitive to cetuximab) were treated with 
cetuximab at 30, 100, or 300 nM for 24 hours, respectively, and Western blotting for p-ERK 
and ERK was performed. β-actin was used as a loading control. C) Quantitative analysis of 
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Western blot data by densitometry. Western blot data were scanned by densitometry and 
analyzed using Image J software. The p-ERK signal was normalized to the corresponding 
total ERK signal and then set to 100% for untreated controls. Error bars show mean ± SD. 
P-values were determined using Student’s t test. *p <0.001. C) Expression of PARP and 
cleaved PARP in CCK-81 or Caco-2 cells. The cells were treated with cetuximab (100 nM) or 
vehicle for 5 days, and Western blotting for PARP and cleaved PARP was performed. β-actin 
was used as a loading control.  
 
Figure 5. 
Immunohistochemical analysis of EGFR expression in CRC tissue. A) The representative 
staining patterns of “marked decrease” (case 5, a-c), “moderate decrease” (case 12, d-f), and 
“no change” (case 9, g-i) in immunoreactivity for EGFR. a, d, g, H&E staining; b, e, h, before 
treatment; c, f, I, after treatment. Bar, 100 µm. B) Waterfall plots of best tumor response in 
CRC patients treated with anti-EGFR monoclonal antibody. Response was evaluated 
according to RECIST version 1.1. C) Correlation of EGFR immunoreactivity and response to 
anti-EGFR antibody. The numbers of patients in the “no change”, “moderate decrease”, and 
“marked decrease” categories were compared between responder and non-responder groups 
using the chi-square test. 
Table 1 Baseline characteristics of patients
Combination Time from last chemotherapy
chemotherapy dose to tissue acquisition (days)
1 F 66 D cetuximab well differentiated type FOLFIRI 4 14
2 M 57 R cetuximab well > moderately differentiated type FOLFOX 4 27
3 M 66 S cetuximab moderately differentiated type FOLFOX 6 27
4 M 50 S cetuximab moderately differentiated type FOLFIRI 5 33
5 F 45 S cetuximab moderately differentiated type FOLFOX 4 41
6 M 72 C cetuximab moderately differentiated type IRI 5 22
7 M 65 R cetuximab moderately differentiated type FOLFIRI 6 20
8 M 60 R panitumumab poorly differentiated type FOLFOX 3 99
9 M 70 R cetuximab moderately differentiated type FOLFIRI 3 45
10 F 47 S cetuximab well differentiated type IRI 7 16
11 M 36 R panitumumab well differentiated type FOLFOX 7 28
12 M 72 R panitumumab well differentiated type IRIS 2 34
13 M 64 S panitumumab well differentiated type IRIS 4 25
M, male ; F, female ; C, cecum ; D, descending colon ;  S, sigmoid colon ; R, rectum ;
mAbs, monoclonal antibodies ; FOLFIRI, irinotecan, leucovorin and fluorouracil ; 
FOLFOX, oxaliplatin, leucovorin and fluorouracil ; IRI, irinotecan ; IRIS, irinotecan and S-1. 
CycleNo. Sex Age Location Anti-EGFR mAbs Tumor differentiation





